345 related articles for article (PubMed ID: 23482733)
1. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.
Keating AJ; Campbell KB; Guyton JR
Ann Pharmacother; 2013 Mar; 47(3):398-404. PubMed ID: 23482733
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.
Backes JM; Venero CV; Gibson CA; Ruisinger JF; Howard PA; Thompson PD; Moriarty PM
Ann Pharmacother; 2008 Mar; 42(3):341-6. PubMed ID: 18285559
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin.
Goldberg AS; DeGorter MK; Ban MR; Kim RB; Hegele RA
Can J Cardiol; 2013 Aug; 29(8):915-9. PubMed ID: 23465343
[TBL] [Abstract][Full Text] [Related]
4. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.
Plakogiannis R; Cohen H
Ann Pharmacother; 2007 Jan; 41(1):106-10. PubMed ID: 17200427
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin in the management of hyperlipidemia.
Cheng JW
Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.
Kennedy SP; Barnas GP; Schmidt MJ; Glisczinski MS; Paniagua AC
J Clin Lipidol; 2011; 5(4):308-15. PubMed ID: 21784377
[TBL] [Abstract][Full Text] [Related]
7. Expanding options with a wider range of rosuvastatin doses.
Olsson AG
Clin Ther; 2006 Nov; 28(11):1747-63. PubMed ID: 17212997
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
9. Statin intolerance.
Ahmad Z
Am J Cardiol; 2014 May; 113(10):1765-71. PubMed ID: 24792743
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidemia: management using optimal lipid-lowering therapy.
Ito MK
Ann Pharmacother; 2012 Oct; 46(10):1368-81. PubMed ID: 23032652
[TBL] [Abstract][Full Text] [Related]
11. Non-every day statin administration--a literature review.
Elis A; Lishner M
Eur J Intern Med; 2012 Jul; 23(5):474-8. PubMed ID: 22726380
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
13. Effects of once weekly rosuvastatin among patients with a prior statin intolerance.
Backes JM; Moriarty PM; Ruisinger JF; Gibson CA
Am J Cardiol; 2007 Aug; 100(3):554-5. PubMed ID: 17659946
[TBL] [Abstract][Full Text] [Related]
14. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance.
Ruisinger JF; Backes JM; Gibson CA; Moriarty PM
Am J Cardiol; 2009 Feb; 103(3):393-4. PubMed ID: 19166695
[TBL] [Abstract][Full Text] [Related]
15. Statin-induced myopathy: a review and update.
Abd TT; Jacobson TA
Expert Opin Drug Saf; 2011 May; 10(3):373-87. PubMed ID: 21342078
[TBL] [Abstract][Full Text] [Related]
16. Narrative review: statin-related myopathy.
Joy TR; Hegele RA
Ann Intern Med; 2009 Jun; 150(12):858-68. PubMed ID: 19528564
[TBL] [Abstract][Full Text] [Related]
17. Does simvastatin cause more myotoxicity compared with other statins?
Backes JM; Howard PA; Ruisinger JF; Moriarty PM
Ann Pharmacother; 2009 Dec; 43(12):2012-20. PubMed ID: 19920157
[TBL] [Abstract][Full Text] [Related]
18. Preprocedural statin therapy in percutaneous coronary intervention.
Cahoon WD; Crouch MA
Ann Pharmacother; 2007 Oct; 41(10):1687-93. PubMed ID: 17712042
[TBL] [Abstract][Full Text] [Related]
19. Alternate day rosuvastatin, an underutilized option in statin intolerant hyperlipidemic patients: a case report and literature review.
Gopalagowda BH; Cutchins C; Cutchins DC; Peiris AN
Tenn Med; 2011 Feb; 104(2):49-51. PubMed ID: 21387899
[TBL] [Abstract][Full Text] [Related]
20. Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients.
Berta E; Harangi M; Zsíros N; Nagy EV; Paragh G; Bodor M
Pharmazie; 2014 Jun; 69(6):420-3. PubMed ID: 24974574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
